Stephan Windecker
Declaration of interest
| Function | Company |
|---|---|
| Grants/research support | Abbott Vascular |
| Grants/research support | Biosensors International |
| Grants/research support | Boston Scientific |
| Grants/research support | Medtronic |
Latest contributions
The PCR-EAPCI Textbook is pleased to announce a new Editor-in-Chief!
22 May 2025
A formal handover took place on Wednesday, 21 May, in Paris during EuroPCR 2025, marking the transition from Stephan Windecker, former Editor-in-Chief, to Robert Byrne, who now assumes the role as the newly appointed Editor-in-Chief of this leading educational resource for interventional cardiologists.
FAITAVI - Major Late-Breaking Trial from EuroPCR 2025
22 May 2025 – From EuroPCR 2025
Presented at EuroPCR 2025, the FAITAVI trial brings new insights into the management of coronary artery disease in patients undergoing TAVI.
In this PCR Perspectives video, Stephan Windecker and Flavio Ribichini explore how the trial—the first of its kind—compared angiography-guided versus FFR-guided strategies for intermediate coronary lesions....
Coronary artery stents - A comprehensive update of the chapter in The PCR Textbook
18 Jun 2024 – From EuroPCR 2024
Watch this discussion between Miklos Rohla and Stephan Windecker as they delve into the newly updated PCR Textbook chapter on stents, the first update in 6 years. This comprehensive resource includes pre-clinical and clinical findings, randomized trial evidence, and in-depth technical specs for all current stents....
Asymptomatic severe aortic stenosis: Will these trials change my practice?
16 May 2024 – From EuroPCR 2024
This session, in collaboration with Partners in Learning, explores the emerging evidence on the use of transcatheter aortic valve implantation (TAVI) in patients with asymptomatic severe aortic stenosis. It covers data from registries and randomized controlled trials, the current guideline recommendations, and the potential impact of...
Major Late-Breaking Trials from EuroPCR 2024
15 May 2024 – From EuroPCR 2024
This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid...
Late-breaking trials on latest-generation aortic valves and dedicated transcatheter devices
20 Nov 2023 – From PCR London Valves 2023
Find out the outcomes of the main studies on the latest-generation valves and devices presented at PCR LV 2023 to better determine their benefits, performance and interest in the treatment of specific aortic pathologies: REACCESS-2 Study, ACURATE Neo2 PMCF post-market registry, OCEAN-TAVI registry, ShortCut Pivotal Study, and...
The catheter-based treatment revolution is just getting started
19 Nov 2023 – From PCR London Valves 2023
Consult this session to stay updated on the latest advancements in transcatheter aortic valve implantations and interventions for tricuspid regurgitation. Gain insights into how recent evidence and innovations are reshaping the treatment landscape for valvular heart disease.
Second time TAVI (TAV-in-TAV) - Not as simple as it looks
19 Nov 2023 – From PCR London Valves 2023
Although it is still rare, TAV-in-TAV is likely to become more frequent, as TAVI is increasingly implanted in younger patients. Harmonizing data in this area will therefore help to improve outcomes, the quality of which depends on site experience, bearing in mind that for the time...
5 year predictions for TAVI as a therapy for aortic stenosis
20 May 2023 – From EuroPCR 2023
Join Andreas Baumbach and Stephan Windecker in a discussion on the future of TAVI, which represents a significant change in the approach to treating patients with aortic stenosis. The conversation revolves around various topics such as the diagnosis process, the discrepancies in access to TAVI among different countries,...
Emerging indications for TAVI
18 May 2023 – From EuroPCR 2023
Consult this session if you want to learn about emergent indications of transcatheter treatment of aortic valve disease, to appreciate current gaps in the evidence base and hear about upcoming clinical trials, and to highlight new technologies that will address these treatment gaps.
Meaningful innovations in interventional cardiology
18 May 2023 – From EuroPCR 2023
In this session, watch the case of a 56-year-old man with HTN, DM, stable CAD, PFO and previous ischaemic stroke, who presented with severely calcified CTO lesion on proximal LAD and significant mid-RCA lesion, and find out how he was treated LIVE... among others!
EuroPCR 2023 Hotlines/Late-Breaking Trials: focus on stent technology
17 May 2023 – From EuroPCR 2023
If you would like to learn more about the latest findings on stent techhnology, check-out this session in which speakers reviewed a series of recent trials, among them: 12-month primary endpoint outcomes of the BIOADAPTOR-RCT; Final 5-year results from the blinded ABSORB IV trial ; BIOMAG-I:...
Transcatheter mitral valve intervention is progressing more slowly than expected: why is it happening? And what can we do? Root causes, challenges and opportunities
28 Nov 2022 – From PCR London Valves 2022
Consult this session to learn about the latest news in the field of mitral valve intervention and get insights into its current slow progress, which may be caused by clinical, anatomical or technological factors.
Remaining unmet needs and strategies in TAVI
28 Nov 2022 – From PCR London Valves 2022
Watch this session to understand why valve design impacts future patient outcomes and how hemodynamics can impact decision-making and the durability of the TAVI devices. At the end of the session, you'll also get an overview of Medtronic's portfolio.
Challenging scenarios: bioprosthetic valve dysfunction
28 Nov 2022 – From PCR London Valves 2022
Consult this session to learn more about the different causes of bioprosthetic valve dysfunction and the best options (surgical, transcatheter or medical) for the management of patients with this kind of dysfunction, as well as to discover how valve design impacts on durability and what the future holds...
Create the future of TAVI - Optimisation of the procedure and patient pathway
27 Nov 2022 – From PCR London Valves 2022
Dive into this session to discover what can be improved today to be ready to treat future TAVI patient volumes. You'll also learn how to set up a successful TAVI coordinating team and adopt it in your hospital, and how to create a win-win partnership with...
TRISCEND, ACURATE neo2, the LuX-Valve System: Top Late-Breaking Trials from PCR London Vaves 2022
27 Nov 2022 – From PCR London Valves 2022
Discover a selection of PCR London Valves 2022 Late-Breaking Trial submissions and learn more about the latest evidence evidence concerning new transcatheter valve devices, emerging innovative devices as well as highlighted content from the EuroIntervention journal.
Predicting and managing TAVI conduction related disorders
20 May 2022 – From EuroPCR 2022
Get key learnings on conduction disorders after TAVI, the role of temporary pacing devices and different strategies to reduce permanent pacemaker implants to the minimum.
PCR Innovators Day - Innovations for valve treatment: new devices, new tools, new procedures
19 May 2022 – From EuroPCR 2022
Valvular heart disease is probably one of the most innovative areas in cardiovascular medicine at large: tremendous progress has been made both in terms of quality of life and mortality. Technology continues to evolve, as there are still many gaps to be filled, and it is...
A patient-focused transcatheter portfolio of options to treat tricuspid regurgitation
19 May 2022 – From EuroPCR 2022
In this session from EuroPCR 2022, the speakers introduce different options available for treating tricuspid regurgitation. They discuss the anatomical considerations that define suitable candidates and review different transcatheter options and their key differentiators.
Planning for a long run: life-time management of bioprosthetic valve implantation
18 May 2021 – From EuroPCR 2021
Watch this session presented by Stephan Windecker, Anna Sonia Petronio, Mohamed Abdel-Wahab, Lars Sondergaard and Hendrik Treede in order to learn about life-time management strategies of aortic stenosis patients, to discuss evolving multifactorial aspects that influence the choice of aortic stenosis patient treatment, and to explore THV...
TAVI or SAVR for aortic stenosis: which modality for which patient?
22 Nov 2020 – From PCR Valves e-Course 2020
Watch this session if you want to hear the latest evidence guiding the choice between TAVI and SAVR in patients with severe aortic stenosis, to further appreciate the clinical and technical factors that determine the optimal mode of intervention and to integrate these insights into your...
PCR e-Course 2020 Hot line: left atrial appendage closure
27 Jun 2020 – From PCR e-Course 2020
Watch a series of Hot Lines on LAA closure presented during the PCR e-Course 2020, followed by an analysis of the results and their impact on your practice: LAA occlusion vs. NOAC, Amulet IDE Roll-in cohort, identification of potential LAAC candidates.
LAA occlusion vs. novel oral anticoagulation in atrial fibrillation
27 Jun 2020 – From PCR e-Course 2020
Learn which patients may benefit from LAA Occlusion (LAAO) vs. long term anticoagulation, and access the latest data of LAAO vs NOAC from a substantial cohort in a propensity score matched study to find out what impact it might have medium and longer term.
Videos included on...
CABG or PCI in patients with left main coronary artery disease
27 Jun 2020 – From PCR e-Course 2020
Watch this session if you want to be updated on clinical outcomes in patients with left main lesion treated by PCI or CABG and to understand the different criteria who play a major role in decision making between PCI and CABG.
This session was originally presented during...
Abstracts on TAVI - PCR e-Course 2020
25 Jun 2020 – From PCR e-Course 2020
View a selection of abstracts from PCR e-Course 2020 on the topic of TAVI:
- Use of the FlexNav delivery system in challenging horizontal aortic anatomy
- Clinical and haemodynamic outcomes after self-expanding TAVR in failed SAVs
- Hemodynamic assessment of patients with severe AS and normal EF undergoing TAVI
- FORWARD PRO one...
The new paradigm for coronary interventions
Watch this session to understand indications for DEB vs. DES & the potential advantage of a sustained sirolimus release when utilised in a DEB, and to get insights into the breakthrough technology of SELUTION SLR & its initial clinical data & clinical experience.
Speakers: Stephan Windecker, Robert...
The Heart Team 2.0 – Where will we be in 2030?
19 Nov 2019 – From PCR London Valves 2019
Consult this session on the Heart Team 2.0 to gain insight into what the future holds for cardiologists, based on clinical evidence, trends in structural heart disease, artificial intelligence, 3D printing, and more!
Spotlight - Challenges for the Heart Team I - A new interventional paradigm for aortic valve disease
18 Nov 2019 – From PCR London Valves 2019
Consult this session on aortic valve disease to learn more about the impact of the latest evidence concerning TAVI vs. SAVR on Heart Team discussions and patient choice (clinical and anatomical characteristics, redistribution of resources and training...), and discover how you and your colleagues can apply this information in...
Innovations in TAVI technique and technology to address evolving patient needs
18 Nov 2019 – From PCR London Valves 2019
Consult this session to learn all about the innovations in TAVI technique and technology, adapting to the changing needs of younger and lower risk patients, and discover how to optimise TAVI procedural outcomes and minimise the need for permanent pacemaker implantation and how to use Evolut PRO+ valve...
